Compare IDEXX Laboratories, Inc. (IDXX) vs Mattel Inc (MAT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Mattel Inc — how do they compare? IDEXX Laboratories, Inc. trades at $569.65 (market cap $46.22B), while Mattel Inc trades at $15.05 (market cap $4.30B). The key difference: IDEXX Laboratories, Inc. is far larger — about 10.7× Mattel Inc's market cap. Which is the better fit depends on your goals.
| IDXX | MAT | |
|---|---|---|
Market Cap | $46.22B | $4.30B |
Sector | Health | Consumer Cyclical |
52-Week High | $766.68 | $22.16 |
52-Week Low | $526.44 | $13.05 |
Enterprise Value | $47.12B | $6.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $571.44, down 4.08% over the past day, amid a mixed technical and strong fundamental backdrop. The stock shows a bullish trend in moving averages but overbought RSI readings near 73. Recent Q2 2026 earnings beat expectations with 9% organic revenue growth, and the company raised full-year EPS guidance. Profitability remains robust with a 25.03% net income margin and 74.21% ROE.
The outlook is positive given strong earnings momentum, high analyst buy ratings, and a consensus price target of $683.33 implying ~20% upside. Risks include premium valuation multiples and potential market volatility. The stock presents a growth opportunity supported by durable competitive advantages in veterinary diagnostics.
Mattel (MAT) trades at $14.76, up 0.14%, with a bullish technical signal from moving averages. The company reported mixed Q2 2026 results with a 10% revenue beat but an earnings miss, reflecting margin pressure from higher costs. Valuation appears reasonable with a P/E of 11.22 and P/S of 0.84, while profitability metrics like a 7.78% net margin and 20.5% ROE remain solid. Recent news highlights growth from toy-based films and adult collectors, though competitive and cost challenges persist.
The outlook is cautiously optimistic, supported by brand strength and entertainment initiatives, but near-term earnings volatility and discretionary spending sensitivity pose risks. Analyst consensus leans Buy with a $14.00 price target, suggesting modest upside potential from current levels amid ongoing execution scrutiny.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Mattel Inc
Mattel markets toy products that are sold to its wholesale customers and direct to retail consumers. The company offers products for children and families, including toys for infants and preschoolers, girls and boys, youth electronics, handheld and other games, puzzles, educational toys, media-driven products, and plush and fashion-related toys. Mattel's owned portfolio includes Barbie, Hot Wheels, Fisher-Price, Thomas & Friends, and American Girl. In addition, it currently manufactures toy products for its segments both internally and externally (through manufacturing partners). Just over half of its net sales are in North America, while the remainder stem from international markets.
Read more on MAT →
